Yes, SI did say "the committee voted 8-1 to approve Remestemcel"
But they were only tasked with voting on whether they thought it might have "efficacy" based on the evidence presented. Which was fairly low quality evidence with quite a lot of deficiencies. And several of them saif they thought it was 50/50 but voted yes to give it the benefit of the doubt.
Thats hardly convincing and the committee had no mandate or power to vote to "approve" it.
Ann: Mesoblast Completes Institutional Allocation, page-185
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.34%) |
Mkt cap ! $1.724B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $18.15M | 12.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3418 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 24361 | 5 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |